ARTICLE | Finance
Disrupting detection
Why Artiman returned to lead CellMax's $9M A-1 round
August 1, 2016 7:00 AM UTC
Following the validation and Taiwan launch of CRC-Protect, CellMax Life Inc. has convinced Artiman Ventures to return for seconds and lead a $9 million series A-1 round. The funding will enable the California company to develop the blood-based colorectal cancer diagnostic to monitor disease progression and evaluate the biotech's diagnostic platform for breast and prostate cancer.
Artiman led the company's $5 million A round in 2013. The A-1 round had participation from Acer Inc. (Taiwan:2353; LSE:ACID) founder Stan Shih and undisclosed Taiwanese investors...